SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

UCB SA

Suletud

SektorTervishoid

162.65 -0.06

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

162.2

Max

164.6

Põhinäitajad

By Trading Economics

Sissetulek

649M

857M

Müük

570M

3.4B

P/E

Sektori keskmine

29.562

51.198

Aktsiakasum

2.09

Dividenditootlus

0.87

Kasumimarginaal

25.498

Töötajad

9,052

EBITDA

704M

1.3B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+19.23% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.87%

2.40%

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-4.9B

31B

Eelmine avamishind

162.71

Eelmine sulgemishind

162.65

Uudiste sentiment

By Acuity

50%

50%

166 / 380 Pingereas Healthcare

UCB SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. juuni 2025, 14:31 UTC

Tulu

New York State Retirement Fund Posts 5.84% Annual Investment Return

6. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. juuni 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. juuni 2025, 20:33 UTC

Tulu

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. juuni 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6. juuni 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6. juuni 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6. juuni 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6. juuni 2025, 16:35 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. juuni 2025, 16:34 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. juuni 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6. juuni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. juuni 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. juuni 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6. juuni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. juuni 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6. juuni 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6. juuni 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6. juuni 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6. juuni 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. juuni 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6. juuni 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6. juuni 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6. juuni 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6. juuni 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6. juuni 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. juuni 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6. juuni 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6. juuni 2025, 14:12 UTC

Tulu

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6. juuni 2025, 14:09 UTC

Tulu

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

UCB SA Prognoos

Hinnasiht

By TipRanks

19.23% tõus

12 kuu keskmine prognoos

Keskmine 94.86 EUR  19.23%

Kõrge 125 EUR

Madal 74 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi UCB SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

4

Osta

1

Hoia

2

Müü

Sentiment

By Acuity

166 / 380 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.